A Dose Finding Study for Pain Relief of a Broken Hip
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00926666|
Recruitment Status : Unknown
Verified August 2009 by NHS Greater Glasgow and Clyde.
Recruitment status was: Not yet recruiting
First Posted : June 23, 2009
Last Update Posted : August 4, 2009
Studies have suggested a link with effective pain relief and reduced illness and death in high risk patients. Ultrasound guided nerve blocks have been associated with an increased success rate and allow visualization of all the anatomical structures and the distribution of the local anesthetic on injection. The hospital mortality for patients admitted to hospital from home in the UK in 2006 with a fractured hip is 14.3% (Bottle and Aylin 947-51).
The aim of this clinical trial is to determine the effective dose of local anesthetic to provide pain relief to patients with a broken hip using ultrasound to guide needle insertion. The hospital mortality for patients admitted to hospital from home in the UK in 2006 with a fractured hip was 14.3%. Patients for emergency surgical fixation or replacement of broken hip will be recruited prior to surgical fixation. All patients recruited to this study will receive standard anesthesia and surgical fixation of their broken hip.
The trial can be divided into two sequential parts; the results of part A will be an amount of local anesthetic which will relieve pain of a broken hip in 95% of all patients. Part B will determine the duration of pain relief provided by the amount of local anaesthetic from part A and blood levels of local anesthetic.
In parts A and B a standard pain relieving nerve block to numb the nerves supplying the hip joint will be administered using ultrasound to guide the injection of local anesthetic. The patient will then be observed for 30 minutes during which time the feeling in the upper leg and pain scores will be recorded. Patients with ineffective nerve blocks will be given immediate pain relief and withdrawn from further participation in the study.
In part A the amount of local anesthetic for the next patient will be increased or decreased if the nerve block is ineffective or effective respectively.
In part B the dose will be the same (calculated from the results of part A). In order to determine the duration of pain relief pain scores will be recorded hourly for up to 24 hours. Blood samples will be taken before the pain relieving nerve block and at 5, 10, 20, 30 and 60 minutes afterwards.
|Condition or disease||Intervention/treatment||Phase|
|Femoral Neck Fractures||Drug: Levobupivacaine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Dose Finding Study for Ultrasound Guided Anterior Psoas Compartment Blocks in Patients With a Fractured Neck of Femur?|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||April 2011|
|Estimated Study Completion Date :||April 2011|
- Drug: Levobupivacaine
Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
- Duration of analgesia [ Time Frame: 24 hours after local anaesthetic nerve block ]
- VAS resting acute pain scores [ Time Frame: 10 mins, 20 mins and 30 mins after nerve block ]
- Blood pressure, respiratory rate, pulse and oxygen saturations [ Time Frame: 10 mins, 20 mins and 30 mins after nerve block ]
- Liver function tests [ Time Frame: Before nerve block ]
- Venous blood gases [ Time Frame: before nerve block ]
- Serum levels of levobupivacaine [ Time Frame: At 5, 10, 20, 30 and 60 mins after nerve block ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00926666
|Western Infirmary||Not yet recruiting|
|Glasgow, Lanarkshire, United Kingdom, G11 7AB|
|Contact: malcolm watson, Mb Ch B 00442112069 email@example.com|
|Sub-Investigator: Emily Walker, MM ChB|
|Principal Investigator: Alexander Binning, MB chB|
|Sub-Investigator: Simone Rowell, Mb ChB|
|Principal Investigator:||Malcolm J Watson, MB chB||NHS Greater Glasgow and Clyde|